News stories about Halyard Health (NYSE:HYH) have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Halyard Health earned a news impact score of 0.17 on Accern’s scale. Accern also gave news articles about the medical instruments supplier an impact score of 45.7752394187241 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- Halyard Health (HYH) Earns “Hold” Rating from KeyCorp (americanbankingnews.com)
- Halyard Health Has 34% Upside Potential, KeyBanc Says In Upgrade (finance.yahoo.com)
- Halyard Health (HYH) Rating Increased to Overweight at KeyCorp (americanbankingnews.com)
- Halyard Health dodges one suit, sees damages slashed in another (massdevice.com)
- Halyard Health (HYH) Downgraded by TheStreet (americanbankingnews.com)
HYH has been the topic of a number of analyst reports. KeyCorp raised shares of Halyard Health from a “sector weight” rating to an “overweight” rating in a report on Thursday. Zacks Investment Research downgraded shares of Halyard Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 6th. Finally, ValuEngine upgraded Halyard Health from a “hold” rating to a “buy” rating in a research note on Sunday, December 31st. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $49.33.
Halyard Health (NYSE:HYH) last issued its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.73 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.23. Halyard Health had a return on equity of 6.98% and a net margin of 5.82%. The company had revenue of $428.10 million during the quarter, compared to analyst estimates of $413.94 million. During the same quarter in the previous year, the firm earned $0.50 earnings per share. Halyard Health’s revenue was up 4.4% on a year-over-year basis. sell-side analysts expect that Halyard Health will post 0.96 EPS for the current fiscal year.
Halyard Health Company Profile
Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.
Receive News & Ratings for Halyard Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health and related companies with MarketBeat.com's FREE daily email newsletter.